---
title: "Mira Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286455836.md"
datetime: "2026-05-14T19:06:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286455836.md)
  - [en](https://longbridge.com/en/news/286455836.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286455836.md)
---

# Mira Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.03.

EBIT: As of FY2026 Q1, the actual value is USD -1.148 M.

MIRA Pharmaceuticals, Inc. operates as a single operating and reportable segment, with its Chief Executive Officer reviewing financial information on an aggregate basis for performance evaluation and resource allocation.

#### Financial Performance for the Three Months Ended March 31, 2026 and 2025

-   **Revenues**: MIRA Pharmaceuticals, Inc. reported no revenues for both the three months ended March 31, 2026, and March 31, 2025.
-   **Operating Costs**:
    -   **General and Administrative Expenses**: Decreased to $578,698 in 2026 from $1,490,796 in 2025, primarily due to a $0.8 million decrease in stock-based compensation and a $0.2 million decrease in payroll-related expenses, partially offset by a $0.1 million increase in professional services and other expenses.
    -   **Research and Development Expenses**: Increased to $524,781 in 2026 from $314,404 in 2025, mainly due to an increase in development costs for MIRA-55, with major components including $63,988 for consultants and $460,793 for research in 2026.
    -   **Total Operating Costs**: $1,103,479 in 2026 compared to $1,805,200 in 2025.
-   **Other Income (Expense), Net**: Reported as - $46,673 in 2026, including $44,909 in interest income and - $91,582 loss from equity method investments, compared to $21,421 in 2025, which primarily consisted of interest income.
-   **Net Loss**: MIRA Pharmaceuticals, Inc. incurred a net loss of - $1,150,152 in 2026, an improvement from - $1,783,779 in 2025.

#### Financial Position as of March 31, 2026 and December 31, 2025

-   **Cash**: $4,815,031 as of March 31, 2026, down from $6,346,921 as of December 31, 2025.
-   **Short-term Investments**: $4,591,518 as of March 31, 2026, compared to $4,683,099 as of December 31, 2025.
-   **Total Current Assets**: $9,428,297 as of March 31, 2026, decreasing from $11,058,166 as of December 31, 2025.
-   **Total Current Liabilities**: $114,761 as of March 31, 2026, significantly down from $702,068 as of December 31, 2025.
-   **Stockholders’ Equity**: $9,348,975 as of March 31, 2026, decreased from $10,391,537 as of December 31, 2025.
-   **Accumulated Deficit**: - $40,730,358 as of March 31, 2026, compared to - $39,580,206 as of December 31, 2025.

#### Cash Flow for the Three Months Ended March 31, 2026 and 2025

-   **Net Cash Used in Operating Activities**: - $1,201,283 in 2026, an improvement from - $1,630,027 in 2025, primarily driven by the net loss, partially offset by stock-based compensation expense and loss from equity method investments in 2026.
-   **Net Cash Used in Financing Activities**: - $330,607 in 2026, due to repayment of an advance payable to a related party, compared to $3,181 provided by financing activities in 2025 from the sale of common stock.

#### Operational Metrics and Strategic Outlook

-   **Product Pipeline**: MIRA Pharmaceuticals, Inc. is advancing three product candidates: Ketamir-2 (completed Phase 1, preparing for Phase 2a in chemotherapy-induced peripheral neuropathy), MIRA-55 (preclinical, advancing toward IND-enabling studies for inflammatory pain), and SKNY-1 (preclinical, evaluating development pathways toward IND-enabling studies for weight management and addiction-related indications).
-   **Regulatory Status**: The U.S. Drug Enforcement Administration (DEA) has concluded that Ketamir-2, MIRA-55, and SKNY-1 are not currently considered controlled substances.
-   **Liquidity and Capital Resources Outlook**: MIRA Pharmaceuticals, Inc. expects its current cash and cash equivalents to fund operations into at least the first quarter of 2027. The company has insufficient cash and cash equivalents to support operations for at least 12 months from the report issuance date, which raises substantial doubt about its ability to continue as a going concern. To address this, MIRA Pharmaceuticals, Inc. plans to seek additional capital through public or private equity offerings and strategic transactions.

### Related Stocks

- [MIRA.US](https://longbridge.com/en/quote/MIRA.US.md)

## Related News & Research

- [MIRA highlights SKNY-1 preclinical data in new publication](https://longbridge.com/en/news/286256663.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)
- [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md)
- [Prairie Operating Co. Announces First Quarter 2026 Results and Reaffirms 2026 Guidance | PROP Stock News](https://longbridge.com/en/news/286463109.md)